Key result
In patients with chronic heart failure, hyperhomocysteinemia (>15 μmol/L) was associated with a significantly lower 5-year survival rate compared to those without it (35% vs. 56%, P<0.05).
Why the study?
Does hyperhomocysteinemia predict 5-year mortality in adult patients with chronic heart failure?
Population
134 adult chronic heart failure patients, including non-ischemic and ischemic etiologies.
Comparison
Hyperhomocysteinemia (HHcy > 15 μmol/L) vs CHF patients without HHcy (≤ 15 μmol/L)
Design
Cohort
Follow-up
5 years
Authors
Loading...
Hyperhomocysteinemia may aid risk stratification in chronic HF; leaves open whether it is a modifiable target.
Cohort (n=134)
Does hyperhomocysteinemia predict 5-year mortality in adult patients with chronic heart failure?
Absolute Event Rate: 35% vs 56%
p-value: p=<0.05
Elevated homocysteine levels (>15 μmol/L) are common in chronic heart failure and serve as an independent predictor of 5-year mortality.
Fournier et al. (2015) conducted a cohort in Chronic Heart Failure (n=134). Hyperhomocysteinemia (HHcy > 15 μmol/L) vs. Without hyperhomocysteinemia (≤ 15 μmol/L) was evaluated on Survival rate at 5 years (p=<0.05). In patients with chronic heart failure, hyperhomocysteinemia (>15 μmol/L) was associated with a significantly lower 5-year survival rate compared to those without it (35% vs. 56%, P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: